Lassauniere 2020 [G].

Study characteristics
Patient Sampling	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Patient characteristics and setting	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Index tests	9 tests evaluated, 3 ELISA and 6 LFIA; this entry ( Lassauniere 2020 [G] ) refers to test [G] [G] Test name: Coronavirus Diseases 2019 (COVID‐19) IgM/IgG Ab Test Manufacturer: Artron Laboratories, Burnaby, Canada; Cat # A03‐51‐322 Ab targets: IgM, IgG. Antigens used: NR Test method: CGIA Timing of samples: Samples used: serum Test operators: laboratory staff Definition of test positivity: visible line Blinded to reference standard: no Threshold predefined: yes
Target condition and reference standard(s)	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Flow and timing	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Comparative
Notes